AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Myriad Genetics Plunges 43.4% Amid Contrasting Analyst Views
Generated by AI AgentAinvest Movers Radar
Tuesday, Apr 1, 2025 4:32 am ET1min read
On April 1, 2025,
experienced a significant drop of 43.4% in pre-market trading, marking a substantial decline in its stock value.Piper Sandler upgraded Myriad Genetics from a "neutral" rating to an "overweight" rating, while also increasing their target price for the stock from $11.50 to $12.50. This move reflects a positive outlook on the company's future performance and potential for growth.
J.P. Morgan analyst Rachel Vatnsdal maintained a sell rating for Myriad Genetics, keeping the target price at $20. This contrasting view suggests a more cautious stance on the company's prospects, highlighting the differing opinions among analysts.
Myriad Genetics has secured two new patents from the U.S. Patent and Trademark Office, which are expected to advance the company's tumor genomic testing capabilities. These patents are likely to enhance Myriad Genetics' competitive position in the genetic testing market, potentially driving future growth and innovation.
Ainvest Movers Radar
Knowing stock market today at a glance
Latest Articles
Annaly Capital's Shares Slide 0.82% Amid Dividend Payout Concerns, Institutional Buys Signal Confidence
Dec.26 2025
Kinross Gold Surges 9% on Improved Operations, Market Re-Rating of Risk Profile
Dec.26 2025
JPMorgan Chase (JPM) Plunge 0.80% as Sanctions-linked Account Freezes Trigger Compliance Concerns
Dec.26 2025
PAAS Shares Soar 3.75% on Institutional Buying, 19.3% Revenue Surge to $854.6M
Dec.26 2025
Iovance Biotherapeutics (IOVA) Plunges 30.3% as Q2 Revenue Miss, Workforce Cuts, and Regulatory Setbacks Spur Selling
Dec.26 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet